Alterity Therapeutics has secured an FDA-aligned Phase 3 pathway for ATH434 in multiple system atrophy, with one pivotal study potentially supporting an approval application.
Novartis is acquiring Myricx Bio for up to $1.5 billion to gain control of a new NMT inhibitor payload platform, but the lead antibody-drug conjugates have not yet entered human trials.
ITM’s lutetium-177 edotreotide extended median progression-free survival to 23.9 months versus 14.1 months with everolimus, strengthening its regulatory and commercial case in advanced neuroendocrine tumours.
Discover why Roche and Otsuka-owned Astex are pursuing a $515 million cell-cycle breast cancer programme and what risks remain.
Discover why Ionis' REVEAL enrollment turns obudanersen into a decisive Phase 3 test for Angelman syndrome treatment.
Explore how Agenus BOTBAL achieved 33% three-year survival in refractory MSS colorectal cancer and what Phase 3 must prove next.
Explore how Alzheon’s new valiltramiprosate brain and safety data could reshape oral Alzheimer’s treatment after a Phase 3 setback.
Discover how Natera’s Signatera MRD test may sharpen chemotherapy decisions after colorectal liver surgery and what remains unproven.
Discover how Aurinia’s PRESERVE study could reshape lupus nephritis care by combining Lupkynis with three major biologic therapies.
Discover why Lineage Cell Therapeutics’ OpRegen and OPC1 programmes now face critical delivery, trial design and manufacturing tests.